Orthopedic Surgeons are certainly already engaged with PAR. They know certain patients make good TKR candidates and many DO NOT.
Going too early with a TKR will NOT end well for most given these artifical joints also have a limited life and need to be replaced within 10-15 years.
Anything that can delay or even prevent someone from undertaking this aggressive/last resort surgical pathway will be very attractive for the entire medical profession plus the GOVT (Medicare) and Private Health Insurers.
GPs are desperate to provide better support to OA suffers but also know they have limited options available once OA pain sets in and function diminishes. Zilosul will not only be an alternative option BUT a viable and meaningful one to get these patients active and relatively pain free.
PAR Price at posting:
26.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)